Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri stated, NVO stock has slipped significantly due to a string of bad news. From competing drugs outperforming Novo Nordisk’s Wegovy weight-loss solution to an investigation linking its type 2 diabetes drug Ozempic to a rare eye condition, the company is in a world of hurt. Nevertheless, NVO stock stands as one of the powerhouses in the broader healthcare industry, carrying a m
